Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safety Meta-Analysis Trumped By Long, Large Trial At Spiriva Advisory Panel

Executive Summary

A clinical trial trumps a meta-analysis for assessing drug safety, at least when it's large and well-done - that was the message from FDA's Pulmonary-Allergy Drugs Advisory Committee during its review of an additional indication for Boehringer Ingelheim's Spiriva HandiHaler Nov. 19
Advertisement

Related Content

Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues
Boehringer’s Olodaterol Will Have To Pass LABA Hurdles At January Advisory Committee
FDA Clears Spiriva HandiHaler Of Increased Cardiovascular Risk
FDA Clears Spiriva HandiHaler Of Increased Cardiovascular Risk
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
BI's Spiriva HandiHaler Joins GSK's Advair Diskus In COPD Exacerbations Reduction Claim
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates
Spiriva’s “All-Clear” On CV Safety From FDA Could Raise Bar For COPD Candidates

Topics

Advertisement
UsernamePublicRestriction

Register

PS051716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel